ARTICLE | Clinical News
NeuroVive reports preclinical data for cyclophilin D inhibitor program
February 2, 2018 8:15 PM UTC
NeuroVive Pharmaceutical AB (SSE:NVP; OTCQX:NVEPF) reported preclinical data showing that a cyclophilin D (CYPD) inhibitor from its NVP025 program led to a greater survival rate in a mouse model of lethal mitochondrial myopathy compared with the control group (94% vs. 50%). NeuroVive also said muscle function in the treated arm was improved compared with controls. The study was conducted in collaboration with the Karolinska Institute (Stockholm, Sweden)...
BCIQ Target Profiles